Larry K. Junker v. Medical Components, Inc., Martech Medical Products, Inc.

Docket No. 2021-1649 (https://cafc.uscourts.gov/opinions-orders/21-1649.OPINION.2-10-2022_1906548.pdf)

DYK, REYNA, STOLL

February 10, 2021

Brief Summary:  DC decision finding no invalidity of design patent for invalidity due to pre-critical date offer for sale reversed.

Summary: Medcomp appealed the DC’s grant of Mr. Junker’s motion for summary judgment (SJ) of no invalidity of design patent D450,389 (D’839) under the on-sale bar (Pfaff, US 1998) and finding of willful infringement and damages of about $1.2 million under 35 USC section 289 (recovery of an infringer’s profits from the sale of infringing products).  D’839 is…
Continue Reading DC grant of no invalidity of design patent reversed due to pre-critical date offer for sale

Plasmacam, Inc. v. CNCelectronics, LLC et al.

Docket No. 2021-1689 (https://cafc.uscourts.gov/opinions-orders/21-1689.OPINION.2-3-2022_1902753.pdf)

NEWMAN, DYK, REYNA

February 3, 2021

Brief Summary:  DC grant of Plasmacam’s motion to enforce its version of a settlement agreement reversed and remanded.

Summary:  CNC appealed DC grant of Plasmacam’s motion to enforce its version of a settlement agreement relating to infringement of Plasmacam’s (as exclusive licensee) US 7,071,441 directed to a plasma cutting system.  During settlement negotiations, the parties traded emails in which Plasmacam’s counsel wrote that “[t]he parties will enter into mutual releases which will include releasing CNCElectronics’s downstream customers from liability for infringing…
Continue Reading DC grant of Plasmacam’s motion to enforce its version of a settlement agreement reversed and remanded

GlaxoSmithKline LLC, et al. v. Teva Pharmaceuticals USA, Inc.

Docket No. 2018-1976, -2023

PROST, NEWMAN, MOORE

October 2, 2020

Update (2/11/22):  Petition for rehearing denied.  Judges Moore, Newman, O’Malley, Taranto, Chen and Stoll concurred to address dissents by Judges Prost, Dyk and Reyna, Judge Dyk, and Judge Reyna.  Judge Dyk wrote, e.g., “the more specific and later-enacted provisions of the HatchWaxman Act override the general infringement provisions of the Patent Act” and “[i]t is hard to see how Congress could have intended that a mandated label could be used as evidence of infringement.”  Judge Reyna wrote “that en banc consideration…
Continue Reading Teva’s ANDA carve-out does not save it from induced infringement (“when the provider of an identical product knows of and markets the same product for intended direct infringing activity, the criteria of induced infringement are met”) (petition for rehearing en banc denied (2/11/22))

Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. (USPTO as Intervenor)

Docket No. 2020-2071 (IPRs 2018-01684) (https://cafc.uscourts.gov/opinions-orders/20-2071.OPINION.12-29-2021_1886454.pdf) (Non-Precedential)

DYK, CLEVENGER, TARANTO

December 29, 2021

Brief Summary:  Board IPR decision finding Sanofi’s patents obvious affirmed as substantial evidence supported the motivation to combine and claim constructions analyses.

Summary:  Sanofi appealed Board IPR decision finding US 9,604,008 unpatentable as obvious.  Sanofi argued the Board erred in finding there was a motivation to combined the two prior art references relied upon (Moller and Steenfeld-Jensen).  “The Board found that Steenfeldt-Jensen provided benefits supporting the combination of Møller’s dose-setting approach with Steenfeldt-Jensen’s dose-dispensing approach,…
Continue Reading Board IPR decision finding Sanofi’s claims obvious affirmed due to motivation to combine references and proper claim construction

Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. (USPTO as Intervenor)

Docket No. 2020-2066, -2068-9 (IPRs 2018-01679-80, -82) (https://cafc.uscourts.gov/opinions-orders/20-2066.OPINION.12-29-2021_1886477.pdf) (Non-Precedential)

DYK, CLEVENGER, TARANTO

December 29, 2021

Brief Summary:  Board IPR decision finding Sanofi’s patents obvious because priority application does not provide proper written description for proposed substitute claims affirmed.

Summary:  Sanofi appealed three IPR decisions finding its US 8,992,486 and 9,526,844 relating to pen-type injectors as shown to be invalid for obviousness in part because the Great Britain (GB) priority document (“GB Application”) lacks proper written description for its proposed substitute claims. In the ‘679 IPR, Sanofi’s proposed substitute…
Continue Reading Board IPR decisions finding Sanofi’s injector claims obvious due to lack of written description in priority document affirmed

Evolusion Concepts, Inc. v. HOC Events, Inc., DBA Supertool USA / Juggernaut

Docket No. 2021-1963 and 2021-1987 (https://cafc.uscourts.gov/opinions-orders/21-1963.OPINION.1-14-2022_1893196.pdf)

PROST, TARANTO, CHEN

January 14, 2021

Brief Summary:  DC decisions reversed due to improper claim construction.

Summary:  Evolusion appealed DC grant of summary judgment (SJ) of non-infringement to HOC (2021-1963).  This opinion also addresses the appeal of the DC grant of SJ to Juggernaut on the same grounds (21-1987).  Both decisions were based on the claim construction of Evolusion’s US 8,756,845 directed to firearm magazines in which the DC’s “key ruling was that the term ‘magazine catch bar’…excludes a factory-installed”…
Continue Reading DC decisions reversed-in-part due to improper claim construction findings

Intel Corporation v. Qualcomm Incorporated

Docket No. 2020-1664 (IPR2018-01429) (https://cafc.uscourts.gov/opinions-orders/20-1664.OPINION.12-28-2021_1885985.pdf)

PROST, TARANTO, HUGHES

December 28, 2021

Brief Summary:  Board’s IPR claim construction affirmed but obviousness decision reversed due to “apparent reason to combine” the prior-art elements.

Summary:  Intel appeal PTAB (“Board”) IPR decision finding some of Qualcomm’s claims of US 8,229,043 relating to radio frequency communication systems patentable.  Intel petitioned for IPR of the ‘043 patent with its customer Apple as real parties-in-interest, alleging anticipation by the prior art “Der” reference and obviousness in view of Der and “Razavi” or Der and “Valla”.  The Board found Intel did…
Continue Reading Intel had Article III standing for appeal; Board IPR obviousness decision reversed as Intel showed motivation to combine under KSR

Novartis Pharm. Corp. v. Accord Healthcare, et al. and HEC Pharm Co., Ltd. et al.

Docket No. 2021-1070 (https://cafc.uscourts.gov/opinions-orders/21-1070.OPINION.1-3-2022_1887614.pdf)

MOORE (D), LINN, O’MALLEY

January 3, 2022

Brief Summary:  DC finding Novartis patent not invalid for lack of written description of negative limitation affirmed.

Summary:  HEC appealed DC bench trial decision that Novartis’ US 9,187,405 is not invalid for lack of written description and that HEC’s ANDA infringes.  The Novartis product is a 0.5 mg daily dose of fingolimod hydrochloride (FH) sold as Gileyna for treatment of relapsing-remitting multiple sclerosis (RRMS), and the ‘405 patent is one of three…
Continue Reading FC panel finds negative limitation sufficiently described, affirms DC finding of no invalidity

Sky International AG v. Sky Cinemas LLC

Docket No. 2021-1575 (USPTO Appeal No. 91223952) (https://cafc.uscourts.gov/opinions-orders/21-1575.OPINION.12-17-2021_1881473.pdf) (Non-Precedential)

TARANTO, BRYSON, STOLL

December 17, 2021

Brief Summary:  Board decision finding Sky Int.’s and Sky Cinemas marks unlikely to cause confusion affirmed.

Summary:  Sky International (SKI) opposed a trademark (TM) application filed by Sky Cinemas (SC) for “SKY CINEMAS” for “movie theaters” due to SKI’s prior registration of similar marks including the work “SKY” (SKY NEWS for “broadcasting”, “news agencies”, and “television and radio news reporting” (“standard character marks…‘devoid of potentially distinguishing graphical elements’”).  SC alleged several of SKI’s “registrations were filed…
Continue Reading Board decision finding Sky Cinemas mark unlikely to cause confusion with Sky International’s marks affirmed

Quest Diagnostics Investments LLC v. USPTO

Docket No. 2021-1115 (IPR2019-00738) (https://cafc.uscourts.gov/opinions-orders/21-1115.OPINION.12-27-2021_1885462.pdf) (Non-Precedential)

MOORE, CLEVENGER, STOLL

December 27, 2021

Brief Summary:  Board IPR decision of anticipation and obviousness of Quest’s claims affirmed.

Summary:  Quest appealed Board IPR decision that the challenged claims of US 8,409,862 relating to using mass spectrometry to detect low levels of testosterone in female humans including purifying the testosterone prior to mass spectrometry (MS).  With respect to this appeal, the Board found LabCorp showed claims 8 and 9 would have been obvious in view of Clark in combination with Draisci (both non-patent prior art).  Claims…
Continue Reading IPR decision finding Quest’s testosterone-detection claims obvious affirmed